Killer Cells, Lymphokine-Activated
"Killer Cells, Lymphokine-Activated" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cytolytic lymphocytes with the unique capacity of killing natural killer (NK)-resistant fresh tumor cells. They are INTERLEUKIN-2-activated NK cells that have no MAJOR HISTOCOMPATIBILITY COMPLEX restriction or need for antigen stimulation. LAK cells are used for ADOPTIVE IMMUNOTHERAPY in cancer patients.
Killer Cells, Lymphokine-Activated
- Killer Cells, Lymphokine-Activated
- Cell, Lymphokine-Activated Killer
- Cells, Lymphokine-Activated Killer
- Killer Cell, Lymphokine-Activated
- Killer Cells, Lymphokine Activated
- Lymphokine-Activated Killer Cell
- Lymphokine-Activated Killer Cells
- Lymphokine Activated Killer Cells
- LAK Cells
- Cell, LAK
- Cells, LAK
- LAK Cell
Below are MeSH descriptors whose meaning is more general than "Killer Cells, Lymphokine-Activated".
- Anatomy [A]
- Cells [A11]
- Blood Cells [A11.118]
- Leukocytes [A11.118.637]
- Leukocytes, Mononuclear [A11.118.637.555]
- Cytokine-Induced Killer Cells [A11.118.637.555.283]
- Killer Cells, Lymphokine-Activated [A11.118.637.555.283.500]
- Lymphocytes [A11.118.637.555.567]
- Killer Cells, Natural [A11.118.637.555.567.537]
- Killer Cells, Lymphokine-Activated [A11.118.637.555.567.537.500]
- Hemic and Immune Systems [A15]
- Blood [A15.145]
- Blood Cells [A15.145.229]
- Leukocytes [A220.127.116.117]
- Leukocytes, Mononuclear [A18.104.22.1687.555]
- Cytokine-Induced Killer Cells [A22.214.171.1247.555.283]
- Killer Cells, Lymphokine-Activated [A126.96.36.1997.555.283.500]
- Lymphocytes [A188.8.131.527.555.567]
- Killer Cells, Natural [A184.108.40.2067.555.567.537]
- Killer Cells, Lymphokine-Activated [A220.127.116.117.555.567.537.500]
- Immune System [A15.382]
- Leukocytes [A15.382.490]
- Leukocytes, Mononuclear [A15.382.490.555]
- Cytokine-Induced Killer Cells [A15.382.490.555.283]
- Killer Cells, Lymphokine-Activated [A15.382.490.555.283.500]
- Lymphocytes [A15.382.490.555.567]
- Killer Cells, Natural [A15.382.490.555.567.537]
- Killer Cells, Lymphokine-Activated [A15.382.490.555.567.537.500]
Below are MeSH descriptors whose meaning is more specific than "Killer Cells, Lymphokine-Activated".
This graph shows the total number of publications written about "Killer Cells, Lymphokine-Activated" by people in Harvard Catalyst Profiles by year, and whether "Killer Cells, Lymphokine-Activated" was a major or minor topic of these publication.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
Below are the most recent publications written about "Killer Cells, Lymphokine-Activated" by people in Profiles.
CD16+CD56+ cells are a potential culprit for hematuria in IgA nephropathy. Clin Exp Nephrol. 2015 Apr; 19(2):216-24.
Inducing anti-tumor cytokines and an immune response in melanoma by inhibition of MIA using the peptide AR71. Eur J Dermatol. 2013 Nov-Dec; 23(6):820-5.
T-bet plays a key role in NK-mediated control of melanoma metastatic disease. J Immunol. 2008 Jun 15; 180(12):8004-10.
Immunotherapy of malignant brain tumors. Immunol Rev. 2008 Apr; 222:70-100.
High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy. J Immunother. 2007 Sep; 30(6):596-606.
GalT-KO pigs: is the cup half empty or half full? Transplantation. 2007 Jul 15; 84(1):12-4.
Expression, processing and transcriptional regulation of granulysin in short-term activated human lymphocytes. BMC Immunol. 2007 Jun 27; 8:9.
Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab. Clin Cancer Res. 2007 Apr 15; 13(8):2392-9.
Cytolytic cells induce HMGB1 release from melanoma cell lines. J Leukoc Biol. 2007 Jan; 81(1):75-83.
Gs protein-coupled adenosine receptor signaling and lytic function of activated NK cells. J Immunol. 2005 Oct 01; 175(7):4383-91.